Sanofi India Limited
Sanofi India Limited (SANOFI.NS) Stock Competitors & Peer Comparison
See (SANOFI.NS) competitors and their performances in Stock Market.
Peer Comparison Table: Drug Manufacturers - General Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| SANOFI.NS | ₹3,339.70 | +2.29% | 76.9B | 23.57 | ₹141.70 | +5.88% |
| CIPLA.BO | ₹1,201.10 | +0.65% | 970.2B | 21.37 | ₹56.20 | +1.34% |
| CIPLA.NS | ₹1,200.90 | +0.71% | 970.1B | 21.34 | ₹56.28 | +1.34% |
| ABBOTINDIA.BO | ₹25,911.00 | -1.39% | 550.6B | 36.47 | ₹710.49 | +1.81% |
| ABBOTINDIA.NS | ₹25,895.00 | -1.48% | 550.3B | 36.09 | ₹717.58 | +1.81% |
| GLAXO.BO | ₹2,346.65 | +1.57% | 397.5B | 41.68 | ₹56.30 | +2.34% |
| GLAXO.NS | ₹2,346.60 | +1.52% | 397.5B | 38.90 | ₹60.33 | +2.34% |
| GLAND.BO | ₹1,700.50 | +0.62% | 280.2B | 33.10 | ₹51.37 | +1.07% |
| GLAND.NS | ₹1,700.00 | +0.68% | 280.1B | 33.01 | ₹51.50 | +1.07% |
| PFIZER.NS | ₹4,839.90 | -0.97% | 221.4B | 25.92 | ₹186.69 | +3.38% |
Stock Comparison
SANOFI.NS vs CIPLA.BO Comparison April 2026
SANOFI.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SANOFI.NS stands at 76.9B. In comparison, CIPLA.BO has a market cap of 970.2B. Regarding current trading prices, SANOFI.NS is priced at ₹3,339.70, while CIPLA.BO trades at ₹1,201.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SANOFI.NS currently has a P/E ratio of 23.57, whereas CIPLA.BO's P/E ratio is 21.37. In terms of profitability, SANOFI.NS's ROE is +0.37%, compared to CIPLA.BO's ROE of +0.15%. Regarding short-term risk, SANOFI.NS is more volatile compared to CIPLA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SANOFI.NS.Check CIPLA.BO's competition here
SANOFI.NS vs CIPLA.NS Comparison April 2026
SANOFI.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SANOFI.NS stands at 76.9B. In comparison, CIPLA.NS has a market cap of 970.1B. Regarding current trading prices, SANOFI.NS is priced at ₹3,339.70, while CIPLA.NS trades at ₹1,200.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SANOFI.NS currently has a P/E ratio of 23.57, whereas CIPLA.NS's P/E ratio is 21.34. In terms of profitability, SANOFI.NS's ROE is +0.37%, compared to CIPLA.NS's ROE of +0.15%. Regarding short-term risk, SANOFI.NS is more volatile compared to CIPLA.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SANOFI.NS.Check CIPLA.NS's competition here
SANOFI.NS vs ABBOTINDIA.BO Comparison April 2026
SANOFI.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SANOFI.NS stands at 76.9B. In comparison, ABBOTINDIA.BO has a market cap of 550.6B. Regarding current trading prices, SANOFI.NS is priced at ₹3,339.70, while ABBOTINDIA.BO trades at ₹25,911.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SANOFI.NS currently has a P/E ratio of 23.57, whereas ABBOTINDIA.BO's P/E ratio is 36.47. In terms of profitability, SANOFI.NS's ROE is +0.37%, compared to ABBOTINDIA.BO's ROE of +0.38%. Regarding short-term risk, SANOFI.NS is more volatile compared to ABBOTINDIA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SANOFI.NS.Check ABBOTINDIA.BO's competition here
SANOFI.NS vs ABBOTINDIA.NS Comparison April 2026
SANOFI.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SANOFI.NS stands at 76.9B. In comparison, ABBOTINDIA.NS has a market cap of 550.3B. Regarding current trading prices, SANOFI.NS is priced at ₹3,339.70, while ABBOTINDIA.NS trades at ₹25,895.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SANOFI.NS currently has a P/E ratio of 23.57, whereas ABBOTINDIA.NS's P/E ratio is 36.09. In terms of profitability, SANOFI.NS's ROE is +0.37%, compared to ABBOTINDIA.NS's ROE of +0.38%. Regarding short-term risk, SANOFI.NS is more volatile compared to ABBOTINDIA.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SANOFI.NS.Check ABBOTINDIA.NS's competition here
SANOFI.NS vs GLAXO.BO Comparison April 2026
SANOFI.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SANOFI.NS stands at 76.9B. In comparison, GLAXO.BO has a market cap of 397.5B. Regarding current trading prices, SANOFI.NS is priced at ₹3,339.70, while GLAXO.BO trades at ₹2,346.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SANOFI.NS currently has a P/E ratio of 23.57, whereas GLAXO.BO's P/E ratio is 41.68. In terms of profitability, SANOFI.NS's ROE is +0.37%, compared to GLAXO.BO's ROE of +0.56%. Regarding short-term risk, SANOFI.NS is more volatile compared to GLAXO.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SANOFI.NS.Check GLAXO.BO's competition here
SANOFI.NS vs GLAXO.NS Comparison April 2026
SANOFI.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SANOFI.NS stands at 76.9B. In comparison, GLAXO.NS has a market cap of 397.5B. Regarding current trading prices, SANOFI.NS is priced at ₹3,339.70, while GLAXO.NS trades at ₹2,346.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SANOFI.NS currently has a P/E ratio of 23.57, whereas GLAXO.NS's P/E ratio is 38.90. In terms of profitability, SANOFI.NS's ROE is +0.37%, compared to GLAXO.NS's ROE of +0.56%. Regarding short-term risk, SANOFI.NS is less volatile compared to GLAXO.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SANOFI.NS.Check GLAXO.NS's competition here
SANOFI.NS vs GLAND.BO Comparison April 2026
SANOFI.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SANOFI.NS stands at 76.9B. In comparison, GLAND.BO has a market cap of 280.2B. Regarding current trading prices, SANOFI.NS is priced at ₹3,339.70, while GLAND.BO trades at ₹1,700.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SANOFI.NS currently has a P/E ratio of 23.57, whereas GLAND.BO's P/E ratio is 33.10. In terms of profitability, SANOFI.NS's ROE is +0.37%, compared to GLAND.BO's ROE of +0.09%. Regarding short-term risk, SANOFI.NS is less volatile compared to GLAND.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SANOFI.NS.Check GLAND.BO's competition here
SANOFI.NS vs GLAND.NS Comparison April 2026
SANOFI.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SANOFI.NS stands at 76.9B. In comparison, GLAND.NS has a market cap of 280.1B. Regarding current trading prices, SANOFI.NS is priced at ₹3,339.70, while GLAND.NS trades at ₹1,700.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SANOFI.NS currently has a P/E ratio of 23.57, whereas GLAND.NS's P/E ratio is 33.01. In terms of profitability, SANOFI.NS's ROE is +0.37%, compared to GLAND.NS's ROE of +0.09%. Regarding short-term risk, SANOFI.NS is less volatile compared to GLAND.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SANOFI.NS.Check GLAND.NS's competition here
SANOFI.NS vs PFIZER.NS Comparison April 2026
SANOFI.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SANOFI.NS stands at 76.9B. In comparison, PFIZER.NS has a market cap of 221.4B. Regarding current trading prices, SANOFI.NS is priced at ₹3,339.70, while PFIZER.NS trades at ₹4,839.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SANOFI.NS currently has a P/E ratio of 23.57, whereas PFIZER.NS's P/E ratio is 25.92. In terms of profitability, SANOFI.NS's ROE is +0.37%, compared to PFIZER.NS's ROE of +0.21%. Regarding short-term risk, SANOFI.NS is more volatile compared to PFIZER.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SANOFI.NS.Check PFIZER.NS's competition here
SANOFI.NS vs PFIZER.BO Comparison April 2026
SANOFI.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SANOFI.NS stands at 76.9B. In comparison, PFIZER.BO has a market cap of 221.4B. Regarding current trading prices, SANOFI.NS is priced at ₹3,339.70, while PFIZER.BO trades at ₹4,839.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SANOFI.NS currently has a P/E ratio of 23.57, whereas PFIZER.BO's P/E ratio is 26.40. In terms of profitability, SANOFI.NS's ROE is +0.37%, compared to PFIZER.BO's ROE of +0.21%. Regarding short-term risk, SANOFI.NS is more volatile compared to PFIZER.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SANOFI.NS.Check PFIZER.BO's competition here
SANOFI.NS vs SANOFICONR.NS Comparison April 2026
SANOFI.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SANOFI.NS stands at 76.9B. In comparison, SANOFICONR.NS has a market cap of 106.9B. Regarding current trading prices, SANOFI.NS is priced at ₹3,339.70, while SANOFICONR.NS trades at ₹4,641.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SANOFI.NS currently has a P/E ratio of 23.57, whereas SANOFICONR.NS's P/E ratio is 44.46. In terms of profitability, SANOFI.NS's ROE is +0.37%, compared to SANOFICONR.NS's ROE of +0.79%. Regarding short-term risk, SANOFI.NS is less volatile compared to SANOFICONR.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SANOFI.NS.Check SANOFICONR.NS's competition here
SANOFI.NS vs SANOFI.BO Comparison April 2026
SANOFI.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SANOFI.NS stands at 76.9B. In comparison, SANOFI.BO has a market cap of 77.1B. Regarding current trading prices, SANOFI.NS is priced at ₹3,339.70, while SANOFI.BO trades at ₹3,349.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SANOFI.NS currently has a P/E ratio of 23.57, whereas SANOFI.BO's P/E ratio is 23.64. In terms of profitability, SANOFI.NS's ROE is +0.37%, compared to SANOFI.BO's ROE of +0.37%. Regarding short-term risk, SANOFI.NS is more volatile compared to SANOFI.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SANOFI.NS.Check SANOFI.BO's competition here
SANOFI.NS vs MARKSANS.BO Comparison April 2026
SANOFI.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SANOFI.NS stands at 76.9B. In comparison, MARKSANS.BO has a market cap of 75.4B. Regarding current trading prices, SANOFI.NS is priced at ₹3,339.70, while MARKSANS.BO trades at ₹166.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SANOFI.NS currently has a P/E ratio of 23.57, whereas MARKSANS.BO's P/E ratio is 21.43. In terms of profitability, SANOFI.NS's ROE is +0.37%, compared to MARKSANS.BO's ROE of +0.14%. Regarding short-term risk, SANOFI.NS is more volatile compared to MARKSANS.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SANOFI.NS.Check MARKSANS.BO's competition here
SANOFI.NS vs MARKSANS.NS Comparison April 2026
SANOFI.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SANOFI.NS stands at 76.9B. In comparison, MARKSANS.NS has a market cap of 75.3B. Regarding current trading prices, SANOFI.NS is priced at ₹3,339.70, while MARKSANS.NS trades at ₹166.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SANOFI.NS currently has a P/E ratio of 23.57, whereas MARKSANS.NS's P/E ratio is 20.91. In terms of profitability, SANOFI.NS's ROE is +0.37%, compared to MARKSANS.NS's ROE of +0.14%. Regarding short-term risk, SANOFI.NS is less volatile compared to MARKSANS.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SANOFI.NS.Check MARKSANS.NS's competition here
SANOFI.NS vs SMSPHARMA.NS Comparison April 2026
SANOFI.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SANOFI.NS stands at 76.9B. In comparison, SMSPHARMA.NS has a market cap of 36.6B. Regarding current trading prices, SANOFI.NS is priced at ₹3,339.70, while SMSPHARMA.NS trades at ₹390.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SANOFI.NS currently has a P/E ratio of 23.57, whereas SMSPHARMA.NS's P/E ratio is 38.98. In terms of profitability, SANOFI.NS's ROE is +0.37%, compared to SMSPHARMA.NS's ROE of +0.14%. Regarding short-term risk, SANOFI.NS is less volatile compared to SMSPHARMA.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SANOFI.NS.Check SMSPHARMA.NS's competition here
SANOFI.NS vs SMSPHARMA.BO Comparison April 2026
SANOFI.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SANOFI.NS stands at 76.9B. In comparison, SMSPHARMA.BO has a market cap of 36.5B. Regarding current trading prices, SANOFI.NS is priced at ₹3,339.70, while SMSPHARMA.BO trades at ₹389.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SANOFI.NS currently has a P/E ratio of 23.57, whereas SMSPHARMA.BO's P/E ratio is 38.86. In terms of profitability, SANOFI.NS's ROE is +0.37%, compared to SMSPHARMA.BO's ROE of +0.14%. Regarding short-term risk, SANOFI.NS is less volatile compared to SMSPHARMA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SANOFI.NS.Check SMSPHARMA.BO's competition here
SANOFI.NS vs SENORES.NS Comparison April 2026
SANOFI.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SANOFI.NS stands at 76.9B. In comparison, SENORES.NS has a market cap of 35.8B. Regarding current trading prices, SANOFI.NS is priced at ₹3,339.70, while SENORES.NS trades at ₹778.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SANOFI.NS currently has a P/E ratio of 23.57, whereas SENORES.NS's P/E ratio is 30.25. In terms of profitability, SANOFI.NS's ROE is +0.37%, compared to SENORES.NS's ROE of +0.13%. Regarding short-term risk, SANOFI.NS is less volatile compared to SENORES.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SANOFI.NS.Check SENORES.NS's competition here
SANOFI.NS vs NGLFINE.BO Comparison April 2026
SANOFI.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SANOFI.NS stands at 76.9B. In comparison, NGLFINE.BO has a market cap of 13.8B. Regarding current trading prices, SANOFI.NS is priced at ₹3,339.70, while NGLFINE.BO trades at ₹2,228.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SANOFI.NS currently has a P/E ratio of 23.57, whereas NGLFINE.BO's P/E ratio is 38.87. In terms of profitability, SANOFI.NS's ROE is +0.37%, compared to NGLFINE.BO's ROE of +0.12%. Regarding short-term risk, SANOFI.NS is less volatile compared to NGLFINE.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SANOFI.NS.Check NGLFINE.BO's competition here
SANOFI.NS vs NGLFINE.NS Comparison April 2026
SANOFI.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SANOFI.NS stands at 76.9B. In comparison, NGLFINE.NS has a market cap of 13.7B. Regarding current trading prices, SANOFI.NS is priced at ₹3,339.70, while NGLFINE.NS trades at ₹2,223.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SANOFI.NS currently has a P/E ratio of 23.57, whereas NGLFINE.NS's P/E ratio is 38.91. In terms of profitability, SANOFI.NS's ROE is +0.37%, compared to NGLFINE.NS's ROE of +0.12%. Regarding short-term risk, SANOFI.NS is less volatile compared to NGLFINE.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SANOFI.NS.Check NGLFINE.NS's competition here
SANOFI.NS vs TTKHLTCARE.NS Comparison April 2026
SANOFI.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SANOFI.NS stands at 76.9B. In comparison, TTKHLTCARE.NS has a market cap of 11.1B. Regarding current trading prices, SANOFI.NS is priced at ₹3,339.70, while TTKHLTCARE.NS trades at ₹787.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SANOFI.NS currently has a P/E ratio of 23.57, whereas TTKHLTCARE.NS's P/E ratio is 18.51. In terms of profitability, SANOFI.NS's ROE is +0.37%, compared to TTKHLTCARE.NS's ROE of +0.06%. Regarding short-term risk, SANOFI.NS is less volatile compared to TTKHLTCARE.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SANOFI.NS.Check TTKHLTCARE.NS's competition here
SANOFI.NS vs KOPRAN.NS Comparison April 2026
SANOFI.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SANOFI.NS stands at 76.9B. In comparison, KOPRAN.NS has a market cap of 6.1B. Regarding current trading prices, SANOFI.NS is priced at ₹3,339.70, while KOPRAN.NS trades at ₹125.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SANOFI.NS currently has a P/E ratio of 23.57, whereas KOPRAN.NS's P/E ratio is 36.69. In terms of profitability, SANOFI.NS's ROE is +0.37%, compared to KOPRAN.NS's ROE of +0.03%. Regarding short-term risk, SANOFI.NS is less volatile compared to KOPRAN.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SANOFI.NS.Check KOPRAN.NS's competition here
SANOFI.NS vs KOPRAN.BO Comparison April 2026
SANOFI.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SANOFI.NS stands at 76.9B. In comparison, KOPRAN.BO has a market cap of 6B. Regarding current trading prices, SANOFI.NS is priced at ₹3,339.70, while KOPRAN.BO trades at ₹125.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SANOFI.NS currently has a P/E ratio of 23.57, whereas KOPRAN.BO's P/E ratio is 36.62. In terms of profitability, SANOFI.NS's ROE is +0.37%, compared to KOPRAN.BO's ROE of +0.03%. Regarding short-term risk, SANOFI.NS is less volatile compared to KOPRAN.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SANOFI.NS.Check KOPRAN.BO's competition here